Development of a liposomal formulation of a TKI: the active loading of erlotinib.HCl
Schelker, C.; Trap, V.; Boechard, G.; Nowak-Sliwinska, P.
Show abstract
Erlotinib.HCl is a tyrosine kinase inhibitor that is used to treat NSCLC and pancreatic cancer in combination with gemcitabine. It is associated with severe adverse effects. This has led researchers to explore encapsulation strategies to reduce these effects. At the same time, previous studies have investigated diverse forms of nanoparticle-based delivery systems for erlotinib.HCl, active loading into liposomes remains unexplored. In this study, we report the first successful active loading of erlotinib.HCl into liposomes. A critical step in nanomedicine development is its translation to clinical settings. Current studies typically progress from 2D cell culture to mouse models. The former lacks complexity, while the latter lacks relevant human physiology. We believe there is a gap between the two models. Therefore, we evaluated our formulation using both traditional cell lines and patient-derived organoids (PDOs). Our findings demonstrate successful active loading of erlotinib.HCl into liposomes. Comparative analysis revealed significant differences in both toxicity profiles and cellular uptake between 2D cell lines and PDOs, highlighting the importance of using complementary model systems in nanomedicine development.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Triggered Release from Thermosensitive Liposomes Improves Tumor Targeting of Vinorelbine 96%
- Transdermal Delivery of Ultradeformable Cationic Liposomes Complexed with miR211-5p (UCL-211) Stabilizes BRAFV600E+ Melanocytic Nevi 95%
- Nor-LAAM loaded PLGA Microparticles for Treating Opioid Use Disorder 94%
Similar papers in this journal
- Analytical Comparability to Evaluate Impact of Manufacturing Changes of ARX788, an Anti-HER2 ADC in Late-Stage Clinical Development 94%
- Synthesis and characterization of peptide conjugated human serum albumin nanoparticles for targeted cardiac uptake and drug delivery. 93%
- Statin-dye conjugates for selective targeting of KRAS mutant cancer cells 93%
Similar papers in this journal
Similar papers in this journal
- Fluence rate-dependent kinetics of light-triggered liposomal doxorubicin assessed by quantitative fluorescence-based endoscopic probe 92%
- Identification of a cardiac glycoside exhibiting favorable brain bioavailability and potency for reducing levels of the cellular prion protein 91%
- Carbon dots boost dsRNA delivery in plants and increase local and systemic siRNA production 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.